News for BioMarin Pharmaceutical Stock (BMRN)

BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy

Zacks Investment Research • 01/11/21

BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set

PRNewsWire • 01/10/21

Primecap Curbs Holdings of Cree, BioMarin Pharmaceutical

GuruFocus • 01/08/21

ALXN or BMRN: Which Is the Better Value Stock Right Now?

Zacks Investment Research • 01/07/21

BioMarin, Alkermes, Ionis: Are These Health Care Stocks Set To Outperform In 2021?

Forbes • 01/04/21

With Alexion Off the Board, Amarin and Biomarin Are Attractive Acquisition Targets

GuruFocus • 12/24/20

7 Undervalued Stocks That Could Soar in 2021

InvestorPlace • 12/21/20

4 Biotechs That Could Be Potential Acquisition Targets in 2021

Zacks Investment Research • 12/17/20

Bluebird Bio, Biomarin Tabbed as Top Acquisition Targets

GuruFocus • 12/17/20

Goldman Sachs Adds Pharmaceutical Giant to Conviction List of Top Stocks to Buy

24/7 Wall Street • 12/16/20

Top Biotech Stocks for Q1 2021

Investopedia • 12/09/20

Why Is BioMarin (BMRN) Up 6.1% Since Last Earnings Report?

Zacks Investment Research • 12/05/20

FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Reminds BioMarin Pharmaceutical Inc. Investors of Important November 24 Deadline in Securities Class Action - BMRN

Newsfile Corp • 11/24/20

DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Business Wire • 11/24/20

BIOMARIN 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN

PRNewsWire • 11/24/20

BMRN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 24, 2020 in the Class Action Filed on Behalf of BioMarin Pharmaceutical Inc. Limited Shareholders

Newsfile Corp • 11/23/20

DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile Corp • 11/23/20

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 24, 2020 - BMRN

Newsfile Corp • 11/23/20

BIOMARIN 48 HOUR DEADLINE ALERT: ClaimsFiler Reminds Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN

Business Wire • 11/23/20

BIOMARIN 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN

Business Wire • 11/21/20

BMRN FINAL DEADLINE: ROSEN, A RESPECTED LAW FIRM, Reminds BioMarin Pharmaceutical Inc. Investors of Important Tuesday Deadline in Securities Class Action - BMRN

Newsfile Corp • 11/21/20

BMRN Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Shareholders of Class Action and Lead Plaintiff Deadline: November 24, 2020

Newsfile Corp • 11/20/20

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioMarin Pharmaceuticals Inc. (BMRN)

Business Wire • 11/20/20

TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile Corp • 11/20/20

TUESDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BioMarin Pharmaceutical Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile Corp • 11/19/20